In this study, all ICU COVID-19 patients had significantly higher plasma levels of the inflammation markers originating from activation of several pathways; SSAO from increased expression of the inflammation-induced protein vascular adhesion protein-148, TNF-α from activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF–κB)65, and IL-1β from activation of the inflammasome66–68 compared to uninfected non-DM individuals. Here, NFKB1 is linked to COVID-19.